Differences in Inflammatory Marker Kinetics between the First and Second Wave of COVID-19 Patients Admitted to the ICU: A Retrospective, Single-Center Study.

C-reactive protein COVID-19 corticosteroid immunomodulation procalcitonin

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
26 Jul 2021
Historique:
received: 25 05 2021
revised: 22 07 2021
accepted: 23 07 2021
entrez: 7 8 2021
pubmed: 8 8 2021
medline: 8 8 2021
Statut: epublish

Résumé

We sought to determine if there was a difference in the longitudinal inflammatory response measured by white blood cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), and ferritin levels between the first and the second COVID-19 wave of ICU patients. In a single-center retrospective observational study, ICU patients were enrolled during the first and second waves of the COVID-19 pandemic. Data were collected on patient demographics, comorbidities, laboratory results, management strategies, and complications during the ICU stay. The inflammatory response was evaluated using WBC count, CRP, PCT, and Ferritin levels on the day of admission until Day 28, respectively. Organ dysfunction was measured by the SOFA score. 65 patients were admitted during the first and 113 patients during the second wave. WBC and ferritin levels were higher in the second wave. CRP and PCT showed markedly different longitudinal kinetics up until day 28 of ICU stay between the first and second wave, with significantly lower levels in the second wave. Steroid and immunomodulatory therapy use was significantly greater in the second wave. Mortality was similar in both waves. We found that there was a significantly reduced inflammatory response in the second wave, which is likely to be attributable to the more widespread use of immunomodulatory therapies.

Sections du résumé

BACKGROUND BACKGROUND
We sought to determine if there was a difference in the longitudinal inflammatory response measured by white blood cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), and ferritin levels between the first and the second COVID-19 wave of ICU patients.
METHODS METHODS
In a single-center retrospective observational study, ICU patients were enrolled during the first and second waves of the COVID-19 pandemic. Data were collected on patient demographics, comorbidities, laboratory results, management strategies, and complications during the ICU stay. The inflammatory response was evaluated using WBC count, CRP, PCT, and Ferritin levels on the day of admission until Day 28, respectively. Organ dysfunction was measured by the SOFA score.
RESULTS RESULTS
65 patients were admitted during the first and 113 patients during the second wave. WBC and ferritin levels were higher in the second wave. CRP and PCT showed markedly different longitudinal kinetics up until day 28 of ICU stay between the first and second wave, with significantly lower levels in the second wave. Steroid and immunomodulatory therapy use was significantly greater in the second wave. Mortality was similar in both waves.
CONCLUSIONS CONCLUSIONS
We found that there was a significantly reduced inflammatory response in the second wave, which is likely to be attributable to the more widespread use of immunomodulatory therapies.

Identifiants

pubmed: 34362074
pii: jcm10153290
doi: 10.3390/jcm10153290
pmc: PMC8348515
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet Respir Med. 2021 May;9(5):e47-e48
pubmed: 33684356
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Infect. 2021 Jun;82(6):e24-e26
pubmed: 33745917
Crit Care. 2020 Sep 18;24(1):561
pubmed: 32948243
JAMA. 2020 Oct 6;324(13):1317-1329
pubmed: 32876697
Intensive Care Med. 2020 Nov;46(11):2035-2047
pubmed: 33034689
Viruses. 2021 Mar 05;13(3):
pubmed: 33807920
Clin Chim Acta. 2020 Oct;509:249-251
pubmed: 32579952
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Antibiotics (Basel). 2021 May 01;10(5):
pubmed: 34062898
Lancet Rheumatol. 2020 Oct;2(10):e594-e602
pubmed: 32864628
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
Am J Respir Crit Care Med. 2021 Jan 15;203(2):192-201
pubmed: 33217246
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Lancet Respir Med. 2020 Mar;8(3):247-257
pubmed: 31948926
EClinicalMedicine. 2020 Jul 31;26:100475
pubmed: 33089115
Clin Chem Lab Med. 2019 Aug 27;57(9):1308-1318
pubmed: 30721141
Lancet Rheumatol. 2021 Jun;3(6):e447-e459
pubmed: 33817665
BMC Med. 2013 Aug 22;11:185
pubmed: 23968282
Lancet Respir Med. 2020 Dec;8(12):1209-1218
pubmed: 32861275
Crit Care Explor. 2020 Oct 19;2(10):e0253
pubmed: 33134944
N Engl J Med. 2020 Nov 19;383(21):2030-2040
pubmed: 33031652
J Clin Med. 2019 Sep 13;8(9):
pubmed: 31540339
Lancet. 2020 Oct 24;396(10259):1345-1352
pubmed: 33031764
Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821
pubmed: 32584597
J Clin Med. 2020 Oct 31;9(11):
pubmed: 33142837

Auteurs

Tamas Szakmany (T)

Critical Care Directorate, Grange University Hospital, Aneurin Bevan University Health Board, Llanyravon, Cwmbran NP44 8YN, UK.
Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

William Tuckwell (W)

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Elsa Harte (E)

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Nick Wetherall (N)

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Saraswathi Ramachandran (S)

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Shannon Price (S)

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Henry Breen (H)

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Charlotte Killick (C)

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Yusuf Cheema (Y)

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Charles King (C)

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Owen Richards (O)

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK.

Classifications MeSH